Molecular Testing in Resectable NSCLC
Solange Peters, MD, PhD, reviews factors to consider for molecular testing in early stage non–small cell lung cancer and discusses the role of single-gene assays and next-generation sequencing panels.
Related Articles
Evolving Treatment Paradigms for Early-Stage Breast Cancers
Expert insights into the evolving therapeutic landscape for early-stage breast cancers, emphasizing targeted therapies and genomic testing for personalized treatment paradigms.
Dr Leary on the FDA Approval of Tovorafenib for Pediatric R/R BRAF+ Low-Grade Glioma
Sarah E. S. Leary, MD, MS, discusses the FDA approval of tovorafenib for pediatric patients with relapsed/refractory, BRAF-mutant low-grade glioma.
OBX-115 With Acetazolamide Induces Safe and Durable Antitumor Responses in Advanced Melanoma
OBX-115 was well tolerated and produced durable antitumor responses in patients with immune checkpoint inhibitor (ICI)-resistant advanced melanoma.
Singh Discusses the Shift Toward Stereotactic Radiation Therapy in Lung Cancer
Raj Singh, MD, discusses the use of stereotactic body radiation therapy and stereotactic radiosurgery in the treatment of patients with lung cancer.
FDA Grants Accelerated Approval to Tovorafenib for Pediatric Relapsed/Refractory BRAF+ Low-Grade Glioma
The FDA granted accelerated approval to tovorafenib for pediatric patients relapsed/refractory low-grade glioma with a BRAF fusion/rearrangement or a BRAF V600 mutation.
Vepdegestrant Shows Potential in ESR1-Mutant ER+/HER2– Breast Cancer
Debu Tripathy, MD, highlights the potential role and significance of vepdegestrant in pretreated ER-positive/HER2-negative breast cancer.
FDA Approves Lutetium Lu 177 Dotatate for Pediatric SSTR+ GEP-NETS
The FDA has approved lutetium Lu 177 dotatate for pediatric patients 12 years of age and older with SSTR)–positive GEP-NETs.
Health Canada Green Lights Subcutaneous Atezolizumab for Lung, Breast, and Liver Cancer
Health Canada has approved subcutaneous atezolizumab for use in patients with lung cancer, breast cancer, and hepatocellular carcinoma.
Tislelizumab Receives EU Approval in 3 Indications for First- and Second-Line NSCLC
Tislelizumab has been approved in Europe across 3 indications in the first and second line for select patients with non–small cell lung cancer.
VCN-01 Demonstrates Early Efficacy, Safety in Pediatric Refractory Retinoblastoma
VCN-01 was safe and elicited signs of antitumor activity in patients with intraocular retinoblastoma that was refractory to chemotherapy or radiotherapy.